Immune-Onc Therapeutics

Science at Our Core. Patients in Our Hearts.

[Immune-Onc Therapeutics @ImmuneOnc]

Phase 1 results for IO-202, our anti-LILRB4 antibody, are now in @Bloodneoplasia. The data show promising activity in #CMML and #AML, offering new hope for patients with limited treatment options.

Read more: https://t.co/occ4adhbGw

[Immune-Onc Therapeutics @ImmuneOnc]

The first patient has been dosed in our global Ph 1b/2 trial evaluating IO-108 for 1st-line treatment of HCC in clinical collaboration with Roche!

A major step forward in our mission to advance cancer care. Learn more: https://t.co/eTXbgkMAns

[Immune-Onc Therapeutics @ImmuneOnc]

We’re back from #ASH2024 and inspired by the energy and engagement around our oral presentation on IO-202 for #CMML. This is a key step toward new hope for people with this rare blood cancer.

Thank you to everyone who joined us.

ICYMI: https://t.co/qnMjahl8ac

[Immune-Onc Therapeutics @ImmuneOnc]

Today, we are proud to present groundbreaking new Phase 1b data on IO-202 for #CMML at #ASH2024!
✔️ CR: 50% | ORR: 66.7%
✔️ High LILRB4 expression: CR: 83%; ORR: 100%
✔️ 40% bridged to transplant
✔️ Additional clinical benefits
Learn more: https://t.co/qnMjahl8ac

[Immune-Onc Therapeutics @ImmuneOnc]

@ImmuneOnc will present important updates on its Phase 1b data on IO-202 for CMML. Don’t miss the oral presentation at #ASH2024 on Monday!

[Immune-Onc Therapeutics @ImmuneOnc]

We’re proud to see @ImmuneOnc's IO-102 Ph 1 #CMML study featured in @LLSusa's announcement highlighting new data showing progress for hard-to-treat blood cancers. Looking forward to sharing more updates on the study at #ASH2024. https://t.co/Adb1t2nSli

[Immune-Onc Therapeutics @ImmuneOnc]

Our Ph 1 data on IO-108 was published in @jitcancer !
· Durable responses in advanced solid tumors
· Promising monotherapy & combo results with pembrolizumab
· Potential to overcome resistance to checkpoint inhibitors
Read the full press release: https://t.co/bScmePooLs

[Immune-Onc Therapeutics @ImmuneOnc]

We're thrilled to announce that Immune-Onc will present new IO-202 data for chronic myelomonocytic leukemia (CMML) at #ASH24! Join us to learn about the potential of our anti-LILRB4 antibody in addressing CMML, an underserved cancer with limited treatments https://t.co/vWEmFZyDof

[Immune-Onc Therapeutics @ImmuneOnc]

New from @ImmuneOnc at #EHA2024! Today, we will present additional positive interim Ph 1b expansion data for IO-202 in #CMML patients. The study shows early and sustained complete remissions among patients, regardless of their prognosis or mutation status. https://t.co/l7ggmOUyk8

[Immune-Onc Therapeutics @ImmuneOnc]

#News: We look forward to presenting interim clinical data from our Phase 1b trial of IO-202 for the treatment of chronic myelomonocytic leukemia (#CMML) at the upcoming #EHA2024 Congress. View the press release for details: https://t.co/shN9syGVJq

[Immune-Onc Therapeutics @ImmuneOnc]

Exciting News! The @SFBusinessTimes recognized our Orphan Drug Designation for IO-202 for #CMML as a recent breakthrough by women-led life sciences companies in the Bay Area. Read more here: https://t.co/p2MQ0zvnlf

[Immune-Onc Therapeutics @ImmuneOnc]

Great news! The FDA has granted IO-202 Orphan Drug Designation for the treatment of chronic myelomonocytic leukemia (CMML). Our Ph 1 study of IO-202 in combination with azacitidine is also currently enrolling newly diagnosed CMML patients. Read more here: https://t.co/EPYdWTG9GC

[Immune-Onc Therapeutics @ImmuneOnc]

Excited to share a collaboration with @Roche evaluating IO-108 in combination with atezolizumab (Tecentriq®) and bevacizumab (Avastin®) for the 1st line treatment of patients with locally advanced or metastatic and/or unresectable hepatocellular carcinoma https://t.co/ZZcDKKPebz

[Immune-Onc Therapeutics @ImmuneOnc]

Next week at the 3rd Tumor Myeloid-Targeted Therapies Summit in Boston, our very own Dr. Luke Chung will present encouraging Ph 1 data for IO-108, our first-in-class antibody targeting LILRB2 (ILT4). We hope to see you there (Wed., 7/19 - 1:30 PM)! https://t.co/2UeoqRkmvY

[Immune-Onc Therapeutics @ImmuneOnc]

#Breaking: Our team and investigators will share the first clinical data on IO-202 (anti-LILRB4), our first-in-class #myeloid #checkpointinhibitor for the treatment of #AML and #CMML at the #EHA2023 congress in Frankfurt. Learn more: https://t.co/3bmjdT97Yi

[Immune-Onc Therapeutics @ImmuneOnc]

#DYK that our first-in-class humanized IgG1 monoclonal antibody, IO-202, targets the myeloid inhibitory receptor LILRB4 to reverse immune suppression in the tumor microenvironment?

Visit our first clinical data presentation showing this in action at #EHA2023.

[Immune-Onc Therapeutics @ImmuneOnc]

Next Tue., May 23, our CEO @charlene_liao and CFO Chris Whitmore look forward to meeting with investors 1:1 at the 2023 Wells Fargo Virtual Private Biotech Symposium to discuss how our platform of #myeloid #checkpointinhibitors is reigniting the field of #immunotherapy. #biotech

[Immune-Onc Therapeutics @ImmuneOnc]

Why are we so excited about #immunotherapy? Because we’re playing a big role in its evolution. This week at #PEGS23 our CEO, @charlene_liao discussed our scientific approach and robust pipeline targeting myeloid checkpoints. Learn more at https://t.co/PCppUGcoG3

[Immune-Onc Therapeutics @ImmuneOnc]

We are presenting clinical data for IO-202 for the first time at #EHA2023 next month! IO-202 is our first-in-class #myeloid #checkpointinhibitor targeting LILRB4 (aka ILT3) for the treatment of #AML and #CMML. Read below for info to attend the presentation ⬇️

[Immune-Onc Therapeutics @ImmuneOnc]

#DYK that myeloid checkpoints could be game-changing targets for the field of #cancerimmunotherapy? Join our CEO @charlene_liao's presentation at the @CHI_Healthtech's 2nd Annual “Emerging Targets for Oncology and Beyond” conference at #PEGS23 next week. See you there!